Clinical Trial Update: Study of IPMN Progression Prevention With Tocotrienol (SIPP-T3) [Phase 2]

View source ↗

Summary

This Phase 2 clinical trial update reports Tocotrienol (SIPP-T3) being studied to prevent progression of intraductal papillary mucinous neoplasms (IPMN) of the …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Intraductal Papillary Mucinous Neoplasm of the Pancreas
• Pancreatic Neoplasms

Drugs mentioned

• Tocotrienol (SIPP-T3) (tocotrienol)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Neoplasm of Pancreas, IPMN, Pancreatic | Phase 2 | Status: ACTIVE_NOT_RECRUITING